Stocks and Investing Stocks and Investing
Wed, October 3, 2018
Tue, October 2, 2018
Mon, October 1, 2018

Jami Rubin Maintained (TEVA) at Strong Buy and Held Target at $30 on, Oct 1st, 2018


Published on 2024-10-26 09:07:15 - WOPRAI, Jami Rubin
  Print publication without navigation


Jami Rubin of Goldman Sachs, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Strong Buy and Held Target at $30 on, Oct 1st, 2018.

Jami has made no other calls on TEVA in the last 4 months.



There are 7 other peers that have a rating on TEVA. Out of the 7 peers that are also analyzing TEVA, 6 agree with Jami's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Tim Chiang of "BTIG" Upgraded from Strong Sell to Hold on, Monday, September 17th, 2018
  • Vamil Divan of "Credit Suisse" Maintained at Hold with Increased Target to $26 on, Monday, September 17th, 2018
  • Douglas Tsao of "Barclays" Maintained at Hold with Increased Target to $23 on, Monday, August 6th, 2018
  • David Risinger of "Morgan Stanley" Maintained at Hold with Increased Target to $20 on, Friday, August 3rd, 2018
  • Louise Chen of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $25 on, Monday, July 16th, 2018
  • Jacob Hughes of "Wells Fargo" Upgraded from Sell to Hold on, Monday, June 18th, 2018


This is the rating of the analyst that currently disagrees with Jami


  • Irina Rivkind Koffler of "Mizuho" Maintained at Strong Buy with Increased Target to $29 on, Monday, September 17th, 2018
Contributing Sources